Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
Drug development for idiopathic pulmonary fibrosis (IPF) has been challenging due to poorly understood disease etiology, unpredictable disease progression, highly heterogeneous patient populations, and a lack of robust pharmacodynamic biomarkers. Moreover, because lung biopsy is invasive and dangero...
| Published in: | Therapeutic Advances in Respiratory Disease |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-06-01
|
| Online Access: | https://doi.org/10.1177/17534666231181537 |